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Abstract
Gonadal failure, along with early pregnancy loss and perinatal death, may be an important filter that limits the propagation
of harmful mutations in the human population. We hypothesized that men with spermatogenic impairment, a disease with
unknown genetic architecture and a common cause of male infertility, are enriched for rare deleterious mutations
compared to men with normal spermatogenesis. After assaying genomewide SNPs and CNVs in 323 Caucasian men with
idiopathic spermatogenic impairment and more than 1,100 controls, we estimate that each rare autosomal deletion
detected in our study multiplicatively changes a man’s risk of disease by 10% (OR 1.10 [1.04–1.16], p,261023), rare X-linked
CNVs by 29%, (OR 1.29 [1.11–1.50], p,161023), and rare Y-linked duplications by 88% (OR 1.88 [1.13–3.13], p,0.03). By
contrasting the properties of our case-specific CNVs with those of CNV callsets from cases of autism, schizophrenia, bipolar
disorder, and intellectual disability, we propose that the CNV burden in spermatogenic impairment is distinct from the
burden of large, dominant mutations described for neurodevelopmental disorders. We identified two patients with
deletions of DMRT1, a gene on chromosome 9p24.3 orthologous to the putative sex determination locus of the avian ZW
chromosome system. In an independent sample of Han Chinese men, we identified 3 more DMRT1 deletions in 979 cases of
idiopathic azoospermia and none in 1,734 controls, and found none in an additional 4,519 controls from public databases.
The combined results indicate that DMRT1 loss-of-function mutations are a risk factor and potential genetic cause of human
spermatogenic failure (frequency of 0.38% in 1306 cases and 0% in 7,754 controls, p = 6.261025). Our study identifies other
recurrent CNVs as potential causes of idiopathic azoospermia and generates hypotheses for directing future studies on the
genetic basis of male infertility and IVF outcomes.
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Introduction
Male infertility is a multifaceted disorder affecting nearly 5% of
men of reproductive age. In spite of its prevalence and a
considerable research effort over the past several decades, the
underlying cause of male infertility is uncharacterized in up to half
of all cases [1]. Some degree of spermatogenic impairment is
present for most male infertility patients, and, in its most severe
form, manifests as azoospermia, the lack of detectable spermato-
zoa in semen, or oligozoospermia, defined by the World Health
Organization as less than 15 million sperm/mL of semen.
Spermatogenesis is a complex multistep process that requires
germ cells to (a) maintain a stable progenitor population through
frequent mitotic divisions, (b) reduce ploidy of the spermatogonial
progenitors from diploid to haploid through meiotic divisions, and
(c) assume highly specialized sperm morphology and function
through spermiogenesis. These steps involve the expression of
thousands of genes and carefully orchestrated interactions between
germ cells and somatic cells within the seminiferous tubules [2]. It
is likely that a large proportion of idiopathic cases of spermato-
genic failure are of uncharacterized genetic origin, but measuring
the heritability of infertility phenotypes has been challenging.
Known genetic causes of non-obstructive azoospermia (NOA)
include deletions in the azoospermia factor (AZF) regions of the Y
chromosome [3], Klinefelter’s syndrome [4], and other cytogenet-
ically visible chromosome aneuploidies and translocations [5].
Beyond these well-established causes, which are observed in 25–
30% of cases, the genetic architecture of spermatogenic impairment
is currently unknown. One might expect a priori that rare or de novo,
large effect mutations will be the central players in genetic infertility,
and indeed other primary infertility phenotypes like disorders of
gonadal development, isolated gonadotropin-releasing hormone
deficiency, and globozoospermia, a disorder of sperm morphology
and function, appear to be caused by essentially Mendelian
mutations operating in a monogenic or oligogenic fashion [6,7,8].
Similarly, recurrent mutations of the AZF region on the Y
chromosome are either completely penetrant (AZFa, AZFb/c) or
highly penetrant (AZFc) risk factors for azoospermia. Our working
model at the start of this study was that additional ‘‘AZF-like’’ loci
existed in the genome, either on the Y chromosome or elsewhere,
and that, much like recent progress in the analysis of developmental
disorders of childhood, a large number of causal point mutations
and submicroscopic deletions could be revealed in idiopathic cases
by the appropriate use of genomic technology.
In this paper, we employ oligonucleotide SNP arrays as
discovery technology to conduct a whole-genome screen for two
rare genetic features in men with spermatogenic failure. First, we
extract and analyze the probe intensity data to find rare copy
number variants (CNVs). A growing number of CNVs have been
associated with a host of complex disease states [9] including
neurological disorders [10,11,12,13], several autoimmune diseases
[14,15], type 2 diabetes [16], cardiovascular disease [17], and
cancer [18,19,20,21]. Now, a role for CNVs in male infertility is
beginning to emerge [22,23,24,25].
As a second approach to identify rare genetic variants, we use a
population genetics modeling framework to identify large homo-
zygous-by-descent (HBD) chromosome segments that may harbor
recessive disease alleles. When applied to consanguineous families,
so-called ‘‘HBD-mapping’’ has been an unequivocal success in
identifying the location of causal variants for simple recessive
monogenic diseases [26]. HBD analysis can also be used to screen
for the location of rare variants in common disease case-control
studies of unrelated individuals, using either a single-locus
association testing framework or by testing for an autozygosity
burden, frequently referred to as ‘‘inbreeding depression’’: an
enrichment of size or predicted functional impact of HBD regions
aggregated across the genome. This approach has produced results
for a growing list of common diseases, including schizophrenia
[27], Alzheimer’s disease [28], breast and prostate cancer [29].
In this study, we screened three cohorts of men with idiopathic
spermatogenic failure in an attempt to identify rare, potentially
causal mutations, and to better understand the genetic architecture
of the disease (Table 1). We found a genomewide enrichment of
large, rare CNVs in men with spermatogenic failure compared to
normozoospermic or unphenotyped men (controls). We also
identify a number of cases with unusual patterns of homozygosity,
possibly the result of recent consanguineous matings. Our results
show that spermatogenic output is a phenotype of the entire
genome, not just the Y chromosome, place spermatogenic failure
firmly among the list of diseases that feature a genomewide burden
of rare deleterious mutations and provide a powerful organizing
principle for understanding male infertility.
Results
First, we attempted to find evidence for undiscovered dominant
causes of spermatogenic failure by studying the genomewide
distribution of CNVs in our primary cohort from Utah: 35 men
with idiopathic non-obstructive azoospermia, 48 men with severe
oligozoospermia, and 62 controls with normal semen analysis. All
cases had previously tested negative when screened for canonical
Y chromosome deletions. Samples were assayed with an Illumina
370K oligonucleotide array that provides both SNP and CNV
content. There was no detectable difference in the average
number of CNVs called per sample among the three groups
(mean=20, azoospermic; 19.5, oligozospermic; 20, normozoo-
spermic), however, the majority of variants (61% on average) in
any one sample were common polymorphisms.
Rare CNV burden is a feature of spermatogenic failure
When restricting our analysis to CNVs with a call frequency of
less than 5%, a subset likely to be enriched for pathogenic events,
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we observed pronounced differences among groups (Table S1).
Azoospermic and oligozoospermic men have nearly twice the
amount of deleted sequence genomewide when compared to
controls (p = 1.761024, Wilcoxon rank sum test), and a nonsig-
nificant 12% increase in the number of deletions per genome.
When examining the even more restricted set of rare CNVs larger
than 100 kb (Dataset S1), these associations are more pronounced:
the rate of deletions in cases was twice that of controls (1.12 vs.
0.55, p = 9.761024) and the amount of deleted sequence 2.6 times
greater in cases (p = 8.861024).
In order to replicate these initial findings, we assayed two
additional cohorts – one group of 61 Caucasian men with severe
spermatogenic impairment and 100 ethnicity-matched, unpheno-
typed controls, both collected at Washington University in St.
Louis (WUSTL), and a larger case cohort of 179 Caucasian men
with idiopathic azoospermia, primarily from medical practices in
Porto, Portugal, matched to an unphenotyped control set of 974
Caucasian men collected by the UK National Blood Service (NBS,
[30]). Although using different array platforms (Text S1), we
observed replication of our initial association (Table S2 and Table
S3); in the WUSTL cohort a 20% increase in the rate (p,0.05)
and in the Porto cohort a 31% increase in rate (p,561023). We
excluded several artifactual explanations for this burden effect,
including specific batch phenomena or population structure (Text
S1, Figures S1, S2, S3, S4, S5). To better characterize these
genomewide signals, we set out to search for clustering of
pathogenic mutations on specific chromosomes.
We focused first on the Y chromosome as it is the location of
most known mutations modulating human spermatogenesis
(Figure 1, Figure S6). Y-linked microdeletions of the AZFa, AZFb,
and AZFc regions are well-established causes of spermatogenic
impairment, and thus we excluded from this study cases with AZF
microdeletions visible by STS PCR. In the array data, we found
no significant difference in the frequency of rare Y deletions
between case and controls groups; however rare duplications were
more abundant in Porto cases compared to the NBS controls (a 3-
fold enrichment in Porto cohort, p = 1.961023). We could classify
the majority (.90%) of our samples to major Y haplogroups using
SNP genotypes (Text S1), and, as expected, most of these samples
fall into the two most common European haplogroups: I (22%)
and R (70%). The observed duplication burden was not an artifact
of differences in major Y haplogroup frequency between cases and
controls, as association was essentially unchanged when only
considering samples with haplogroup R1 (p = 3.361023). Due to
low probe coverage, only one Y-linked duplication was called in
the Utah cohorts (in a control individual) and two in the WUSTL
cohort (both in cases), so this burden of Y duplications was not
replicated.
Next we turned to the X chromosome, which is highly enriched
for genes transcribed in spermatogonia [31]. In the Utah cohorts
there were 71 gains and losses with a frequency of less than 5% on
the X chromosome, cumulatively producing three times as much
aneuploid sequence in azoospermic and oligozoospermic men
compared with normozoospermic men (89 kb/person azoo,
45 kb/person oligo, 27 kb/person normozoospermic men, all
cases versus controls p,0.03). This burden was strongly replicated
in the Porto samples, which displayed a 1.6 fold enrichment of rare
CNV on the X (p= 561024) and the WUSTL samples (31% of
cases with a rare X-linked CNV versus 16% of controls, p = 0.02
by permutation).
The genome-wide signal of CNV burden was not driven solely
by sex chromosome events: considering only autosomal mutations
in Utah samples there was an enrichment of aneuploid sequence in
large deletions in azoospermic men (268 kb/person) and oligozo-
ospermic men (308 kb/person) compared to control men (189 kb/
person, p= 9.861023), and an enrichment in the rate of deletions
in all cases when considering just events .100 kb (1.9 fold
enrichment, p = 661023). In the Porto cohort, there was modest
evidence for a higher rate of rare deletions of all sizes in
azoospermic men (1.27 fold enrichment, not significant) as well as
an increase in total amount of deleted sequence (345 kb/case vs.
258 kb/control, p,0.003).
In order to cleanly summarize our findings across all cohorts, we
fit logistic regression models for each cohort, regressing case status
onto CNV count for different classes of CNV. We also fit a linear
mixed-effects logistic regression model to the total dataset for each
CNV class, treating cohort as a random factor (Figure 1). In each
regression model we controlled for population structure by
including eigenvectors from a genomewide principal components
analysis (Methods). On the basis of the combined analysis, we
estimate that each rare autosomal deletion multiplicatively
changes the odds of spermatogenic impairment by 10% (OR
1.10 [1.04–1.16], p,261023), each rare X-linked CNV (gain or
loss) by 29%, (OR 1.29 [1.11–1.50], p,161023) and each rare Y-
linked duplication by 88% (OR 1.88 [1.13–3.13], p,0.03).
Locus-specific analyses
Deletions of the AZF regions of the Y chromosome are often
mediated by non-allelic homologous recombination (NAHR)
between segmental duplications and are the most common known
cause of spermatogenic failure. Because of their prognostic power
and high rate of recurrence in the population, screening for AZF
deletions is a standard part of the clinical workup for azoospermia.
It would be of high clinical value if additional azoospermia
susceptibility loci with significant recurrence rates could be
identified.
We screened all cohorts for large (.100 kb) rearrangements
flanked by homologous segmental duplications capable of gener-
ating recurrent events by NAHR [32]. There was no significant
enrichment of gains or losses in cases across these hotspot regions
when considered as an aggregate. Due to small sample sizes we
Author Summary
Infertility is a disease that prevents the transmission of
DNA from one generation to the next, and consequently it
has been difficult to study the genetics of infertility using
classical human genetics methods. Now, new technologies
for screening entire genomes for rare and patient-specific
mutations are revolutionizing our understanding of repro-
ductively lethal diseases. Here, we apply techniques for
variation discovery to study a condition called azoosper-
mia, the failure to produce sperm. Large deletions of the Y
chromosome are the primary known genetic risk factor for
azoospermia, and genetic testing for these deletions is
part of the standard treatment for this condition. We have
screened over 300 men with azoospermia for rare
deletions and duplications, and find an enrichment of
these mutations throughout the genome compared to
unaffected men. Our results indicate that sperm produc-
tion is affected by mutations beyond the Y chromosome
and will motivate whole-genome analyses of larger
numbers of men with impaired spermatogenesis. Our
finding of an enrichment of rare deleterious mutations in
men with poor sperm production also raises the possibility
that the slightly increased rate of birth defects reported in
children conceived by in vitro fertilization may have a
genetic basis.
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found no single-locus associations, at these hotspot loci, or
elsewhere, that met the strict criteria of genomewide significance
in both the discovery and replication cohorts. Many of our single-
cohort associations from one platform lack adequate probe
coverage on other platforms for robust replication (Text S1).
However, several loci were significant on joint analysis of all
cohorts.
The best candidate for a novel locus generating NAHR-
mediated infertility risk mutations is a 100 kb segment on
chromosome Xp11.23 flanked by two nearly identical (.99.5%
homology) 16 kb segmental duplications containing the sperm
acrosome gene SPACA5 (Figure 2a, Figure S7). We identified 9
deletions of this locus spread across all patient cohorts (3 in PT, 1
in UT, 5 in WUSTL) compared to 8 in the pooled 1124 controls
(2.8% frequency versus 0.7%, odds ratio = 3.96, p = 0.005, Fisher
exact test). We genotyped the deletion by +/2 PCR in an
additional cohort of 403 men with idiopathic NOA from Weill
Cornell, and observed an additional 3 deletions (Figure S8, Text
S1). In a prior case-control study of intellectual disability,
investigators using qPCR estimated the allele frequency of this
Table 1. Case and control cohorts used in the study.
Cases Controls
Center Phenotype Ethnicity N Analyses Center Ethnicity N Analyses
Utah Azoo/Oligo Caucasian 83 C,A Utah Caucasian 62 C,A
Weill Cornell Azoo Caucasian 420 C,R,A UKNBS Caucasian 974 C
Porto Azoo/Oligo Caucasian 162 C,A Spain Caucasian 622 A
WUSTL Azoo/Oligo Caucasian 61 C,A WUSTL Caucasian 100 C,A
Nanjing Azoo Han Chinese 979 R Nanjing Han Chinese 1734 R
‘N’, number of individuals in the cohort after excluding ethnic outliers and samples with poor data quality. ‘Analyses’, describes whether the cohort was included in
primary CNV analyses (‘C’), replication CNV analyses (‘R’), and autozygosity analyses (‘A’). Note that due to small sample sizes, the 17 Weill Cornell samples with SNP array
data were merged with Porto samples and the combined set treated as a single cohort for the primary CNV analyses. Thus the total number of cases with whole-
genome array data are 83+17+162+61 = 323. Many more samples were sourced from Cornell for replication analysis. Full details of each cohort are available in Text S1.
doi:10.1371/journal.pgen.1003349.t001
Figure 1. Rare variant burden in cases of spermatogenic impairment. We used logistic regression to estimate the influence of copy number
variants (CNVs) on the odds of being diagnosed with impaired spermatogenesis in three case-control cohorts. The estimated odds of spermatogenic
impairment is equal to, or slightly lower than, one when considering autosomal deletions of all frequencies (leftmost panel, shaded grey). However,
when considering only autosomal deletions with call frequencies less than 5%, we observed a progressively increasing risk conferred by events on
the autosomes, the X and the Y chromosomes. A very small number of Y-linked calls were made in cohorts 1 and 3 due to array design, thus we have
only plotted Y-linked rates for cohort 2. Samples with Y-linked AZF deletions were excluded from the study. The odds ratio estimated from fitting a
logistic regression model of total CNV count to disease status is plotted separately for each cohort, as well as the combined set of all cohorts (black
points). Cohort 1 =Utah (Illumina 370K), 2 = Porto and Weill Cornell (Affymetrix 6.0), 3 =WUSTL (Illumina OmniExpress), All =meta-analysis of all three
cohorts. Sample sizes used in CNV analysis are n= 83 cases and 62 controls for cohort 1, n = 183 cases and 974 controls for cohort 2, and n= 61 cases
and 100 controls for cohort 3.
doi:10.1371/journal.pgen.1003349.g001
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deletion to be 0.47% (10/2121) in a large Caucasian male control
cohort [33]. Combining these data, we estimate the allele
frequency of the deletion to be 1.6% in Caucasian cases,
compared to 0.55% in Caucasian controls (OR 3.0, 95% CI
1.31–6.62, p = 0.007). The deleted region contains the X-linked
cancer-testis (CT-X) antigen gene SSX6; the CT-X antigen family
is a highly duplicated gene family on the X chromosome
comprising 10% of all X-linked genes and is expressed specifically
in testis. After controlling for differences in coverage across the
array platforms used in this study, we find a significant enrichment
of rare deletions of CT-X genes in all cases (p = 0.02); this finding
did not extend to duplications or CT antigen genes on the
autosomes (Table 2).
When analyzing all cohorts jointly, our strongest association
(genomewide corrected p-value ,0.002) is to both gains and losses
involving a 200 kb tandem repeat on Yq11.22, DYZ19 (Figure S6,
Figure S9), a human-specific array of 125 bp repeats first
discovered as a novel band of heterochromatin in the Y
chromosome sequencing project [34]. Tandem repeat arrays are
often highly unstable sequence elements that can mutate by both
replication-based and recombination-based (e.g. NAHR) mecha-
nisms. In our data there were 9 gains and 11 losses at DYZ19 in
323 cases (combined frequency 6.1%), compared to 3 gains and 12
losses in 1136 controls (combined frequency 1.3%). While this
finding may ultimately require painstaking technical work to
conclusively validate, we have several reasons to believe the
association is real. First, we have previously shown that it is
possible to identify real copy number changes at VNTR loci using
short oligonucleotide arrays [35]; second, copy number changes at
this locus were identified by multiple platforms in the current
study; third, the association is nominally significant in both the
Utah and Porto cohorts; fourth the locus is within the AZFb/c
region. The direction of copy number changes does appear to
track with haplogroup – while 12/13 duplications occur on the R1
background, 14/15 deletions for which haplogroup could be
determined occur on I or J background. Haplogroup assignments
for the carriers of these CNVs were confirmed by standard short
tandem repeat analysis (Text S1). The strong association between
haplogroup and direction of copy number change is noteworthy; it
may indicate that DYZ19 CNVs are merely correlated with other
functional changes on these chromosomes, or perhaps the
structure of these chromosomes predisposes them to recurrent
gains (R1) or losses (I/J).
The gene DMRT1 is widely believed to be the sex-determina-
tion factor in avians, analogous to SRY in therians, and may play
the same or similar role in all species that are based upon the ZW
sex chromosome system [36]. DMRT1 encodes a transcription
factor that can activate or repress target genes in Sertoli cells and
premeiotic germ cells through sequence-specific binding [37]. In
humans, DMRT1 is located on 9p24.3 in a small cluster with the
related genes DMRT2 and DMRT3. Large terminal deletions of 9p
are a known cause of syndromic XY sex-reversal, and although the
role of the DMRT genes in the 9p deletion syndrome phenotype
has not yet been defined, mouse experiments have shown that
homozygous deletion of DMRT1 causes severe testicular hypopla-
sia [38,39,40].
We found two, perhaps identical, 132 kb deletions spanning
DMRT1 in the Utah cohort in men with azoospermia, and a
1.8 Mb terminal duplication of 9p, spanning these genes, was seen
in a single normozoospermic control from Utah (Figure 2b). All
three of these rearrangements were validated by TaqMan assay
(Figure S10, Text S1). Both men were recruited into the study in
Salt Lake City, UT between 2002 and 2004. They self-reported
their ancestry as Caucasian, and in both cases this assumption was
clearly verified by principal components analysis of their genetic
data (Figure S2). There was no evidence that the two deletion
carriers were closely related upon comparison of their whole-
genome SNP genotypes. Testis biopsies were performed on both
men; these indicated apparent Sertoli cell only syndrome in the
first and spermatocytic arrest in the second. Both men exhibited
apparently normal male habitus and virilization with no pheno-
typic similarities to 9p deletion syndrome.
We obtained Affymetrix 6.0 array data from a previously
published genomewide association study of idiopathic NOA in
Han Chinese [41] comprised of 979 cases and 1734 controls (Text
S1). After processing these samples with our CNV calling pipeline,
we observed an additional 3 deletions of DMRT1 exonic sequence
in cases (0.3%) and none in controls (Figure 2B, Figure S11). From
these combined array data we estimate a frequency of DMRT1
exonic deletion of 0.38% (5/1306) in cases and 0% (0/2858) in
controls (OR= Infinity, [2.0-Inf], p = 0.003). We obtained the two
largest control SNP array datasets in the Database of Genomic
Variants (DGV), representing CNV calls from 4519 samples typed
with platforms of equal or higher probe density to the ones used
here [42,43]. None of these samples contained CNV of any sort
affecting DMRT1. Finally, we screened an additional set of 233
idiopathic NOA cases from Weill Cornell, and 135 controls with
the TaqMan validation assay and identified an additional 3
deletions (2 in cases, 1 in controls, Text S1, Figure S12). As this
qPCR assay interrogates intronic sequence, the functional
consequences of these 3 deletions are unclear. Our array data
have revealed some of the smallest coding deletions of DMRT1
reported to date in humans, and should help to clarify the critical
regions of 9p involved in testicular development and function.
Notably, using a bespoke reanalysis of the intensity data, we did
not see evidence for CNVs involving the gene PRDM9, a recently
characterized zinc finger methyltransferase that appears to control
the location of recombination hotspots in a diversity of mamma-
lian species. Heterozygosity of PRDM9 zinc finger copy number
has been shown to cause sterility in male hybrids of Mus m.
domesticus and Mus m. musculus due to meiotic arrest [44].
Functional impact
The identification of functional or physical annotations
enriched in case-associated CNVs can be a powerful step in
constructing models to classify pathogenic variants. We searched
for significant case-specific aggregation of CNVs in several
classes of functional sequence, including 195 genes previously
shown to result in spermatogenic defects when mutated in the
mouse [45], all protein and non-protein coding genes, and 525
testis genes that are differentially expressed during human
spermatogenesis (Text S1). Deletion of X- or Y-linked exonic
sequence conferred the strongest risk (OR= 1.87 [1.30–2.68],
p,161023). Very similar risk was associated with deletion of
exonic sequence from testis genes differentially expressed during
spermatogenesis, despite the fact that only 15% of these genes
are located on the sex chromosomes (OR= 1.85 [1.01–3.39],
p,0.05). Deletion of any exonic sequence was also associated
with disease (OR= 1.25 [1.07–1.46], p,561023). Deletion of
miRNAs was not associated, nor was deletion of the 195 mouse
spermatogenic genes [45], which were very rarely deleted in
either cases or controls.
We hypothesized that at least some of the functional impact of
CNV burden on fertility was a result of disruption of haploinsuffi-
cient (HI) genes, as has been demonstrated for neuropsychiatric
and developmental disease [46]. For each singleton deletion in our
collections we used a recently described modeling framework to
calculate the probability that the deletion is pathogenic due to
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dominant disruption of a haploinsufficient gene [47]. Much to our
surprise, HI scores from deletions in infertility cases were much
smaller than those from cases of autism and developmental
disorders and in fact indistinguishable from controls (mean HI
score 21.16 in controls, 21.02 in all spermatogenic impairment
cases, p = 0.49 by Wilcoxon rank sum test; Figure 3). Likewise
there was no enrichment of large rearrangements within 45 known
genomic disorder regions in cases [46]. In contrast to previously
Figure 2. Discovery of recurrent deletions in azoospermia. (A) A recurrent microdeletion on Xp11.23 (47765109–47871527 bp, hg18) is a
strong candidate risk factor for spermatogenic failure. The location of deletions (red shades) and duplications (blue shades) in cases and controls are
plotted separately for each cohort. CNVs at this locus appear to arise due to non-allelic homologous recombination between two nearly identical
(.99.5% homology) 16 kb segmental duplications that contain the sperm acrosome gene SPACA5. Also within the CNV region are the genes ZNF630
and the cancer-testis antigen SSX6. We identified 9 deletions of this locus spread across all patient cohorts (3 in PT, 1 in UT, 5 in WUSTL) compared to
8 in the pooled 1124 controls (2.8% frequency versus 0.7%, odds ratio = 3.96, p = 0.005, Fisher exact test). After analysis of an additional 403 cases and
2121 controls, the association is still significant (combined data: 1.6% frequency in cases, 0.55% in controls, OR 3.0, 95% CI = [1.31–6.62], p = 0.007). (B)
We identified two patients with deletion of DMRT1, a gene on 9p24.3 that is orthologous to the putative sex determination locus of the avian ZW
chromosome system [36]. Both men were diagnosed as azoospermic. We validated these deletion calls with a qPCR assay (green star, Figure S9). We
screened Affymetrix 6.0 data from an independent Han Chinese case-control study of NOA and identified an additional 3 deletions of DMRT1 coding
sequence in 979 cases and none in 1734 controls. Finally, we observed no coding deletions of DMRT1 in the two largest control SNP array datasets in
the Database of Genomic Variants, consisting of 4519 samples [42,43]. The combined results indicate that deletion of DMRT1 is a highly penetrant
genetic cause of human spermatogenic failure (frequency of 0.38% in 1306 cases and 0% in 7754 controls, combined p= 6.261025). Patient IDs are
indicated next to each plot (U162_A, U841_A=Utah cohort patients; F3407, F5031, F1060=Nanjing cohort patients).
doi:10.1371/journal.pgen.1003349.g002
Table 2. X-linked cancer-testis antigens deleted in case and control samples.
GENE START** STOP PT/WC UTAH WUSTL CASE COUNT CONTROL COUNT
SSX6{ 47852031 47865013 3 1 5 9 8
SSX1 47999740 48011823 0 1 0 1 2
SSX3 48090806 48101086 0 0 0 0 1
GAGE10 49047068 49063255 0 0 0 0 1
NXF2B 101501974 101613388 1 0 0 1 1
CT47* 119895375 119898693 1 1 0 2 1
CT45* 134674850 134684654 9 0 0 9 21
SPANXA1/A2*{ 140499461 140500526 0 0 0 0 6
MAGEA11{ 148575476 148604507 0 1 0 1 0
MAGEA9{ 148671401 148677206 0 0 0 0 1
MAGEA8{ 148770653 148775266 1 0 0 1 0
Unique Samples 24 (7.3%) 42 (3.7%)***
*Gene or gene family is annotated multiple times on the reference genome; coordinates for the first copy are given.
**Gene coordinates are based on NCBI36.
***Frequency difference between cases and controls, p,0.05.
{Patient-specific deletions of these genes were reported in a study of X-linked CNVs in over 250 azoospermia cases and 300 normospermic controls [58].
doi:10.1371/journal.pgen.1003349.t002
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described diseases that feature CNV burden, spermatogenic
impairment may be more likely to result from large effect recessive
mutations, or perhaps the additive effect of deleterious mutations
across many loci. We sought to uncover support for recessive
mutation load in our cases by assessing the impact of inbreeding,
or elevated rates of homozygosity, on disease risk by applying a
population genetic approach to the SNP genotype data from our
samples [48].
HBD analyses
The major genetic side effect of consanguineous mating is a
genome-wide increase in the probability that both paternal and
maternal alleles are homozygous-by-descent. This probability is
often summarized as the inbreeding coefficient, F, and can be
estimated from analysis of pedigree structure or by direct
observation of genomewide SNP genotypes.
Due to differences in demographic history and culture, the
extent of background homozygosity in the genome is expected to
vary when comparing diverse populations throughout the globe.
The haplotype modeling algorithms implemented in the software
package BEAGLE estimate the background patterns of linkage
disequilibrium and homozygosity across a set of samples, allowing
population-specific information to be used to assess the evidence
that any given section of a genome is likely to be homozygous-by-
descent (HBD). During the course of our study we concluded that
standard PCA-based approaches to stratification are insufficient to
correct for population structure during the analysis of inbreeding,
even when using population genetic methods like BEAGLE (Text
S1, Figure S13). The problem comes not from spurious
identification of HBD, but from spurious association of HBD
with disease status when case and controls are sampled from
groups with different levels of background relatedness. For
instance, in a recent survey of 17 Caucasian cohorts, estimates
of the average inbreeding coefficient, F, varied from 0.09% to
0.61%, with UK-based cohorts showing the lowest F and the one
Portuguese cohort showing the highest [27]. While PCA-based
methods traditionally detect and correct for differences in allele
frequencies among groups, we believe that they do not detect
differences in inbreeding that can be readily incorporated into a
case-control testing framework. In the following section, we use
data from 622 healthy adults from Spain, who we believe form a
more appropriate control group for the Porto case cohort
(Methods, Text S1, Figure S13).
Analyzing each cohort separately, BEAGLE identified 5343
chromosome segments likely to represent HBD regions (HBDRs)
across all samples. We excluded low-level admixture as a spurious
source of HBD (Figure S3). Only three of these segments were
identified as apparent artifacts induced by large heterozygous
deletions (287 kb, 817 kb, and 877 kb in size) and were removed
before subsequent analyses. As expected, the distribution of HBD
across all samples was L-shaped, with the majority of HBDRs
shorter than 1 Mb and a few intermediate and very large events
observed (Figure 4b). The largest HBDR identified spanned all of
chromosome 2 in an azoospermic individual, indicative of
uniparental isodisomy of the entire chromosome. Clinical reports
of UPD2 are extremely rare – there are 7 previous reports of
UPD2 that have been ascertained through association with an
autosomal recessive disorder [49]. In each of these cases a recessive
disorder that lead to clinical presentation was identified. There is
currently no proof of imprinted genes on chromosome 2 from
Figure 3. Disruption of predicted haploinsufficient genes is infrequent in spermatogenic failure. We obtained lists of rare deletions, left
panel, from the Utah and WTCCC control cohorts and, right panel, from cohorts of developmental delay (DECIPHER) [66], autism [67], schizophrenia
[68], bipolar disorder [66,68], and spermatogenic impairment (this study). We used a published method for assessing the likelihood that each deletion
disrupts a haploinsufficient gene [47], summarized as a LOD score, and ordered each cohort by the median LOD(HI) within cases and controls
separately. While the CNVS from DECIPHER (p,1610215), autism (p,1610215), schizophrenia (p,161024) and bipolar disorder (p,0.002) show
significant enrichment of high LOD (HI) scores compared to controls, the infertility cohorts have score distributions indistinguishable from controls.
Two outlier deletions from the infertility cohort are annotated; one is a deletion of WT1, a key gene in gonadal differentiation, and the other is a 1 Mb
deletion involving several genes including MAPK1 and the cancer-testis antigen PRAME. Further review of clinical data from the WT1 carrier showed
signs of cryptorchidism. Abbreviation of azoospermia cohorts: az1, Utah cohort, az2, WUSTL, az3 Porto, az4, Weill-Cornell. Note that for additional
detail we have split the cohort referred to as ‘‘Porto’’ in the main text into two subgroups, az3 and az4, defined by the clinical group that ascertained
the cases.
doi:10.1371/journal.pgen.1003349.g003
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either mouse or human data. We performed whole exome
sequencing on this individual, and using a simple scoring scheme
based on functional annotation and population genetic data,
identified a homozygous missense mutation of the INHBB gene as
the most unusual damaging homozygous lesion in the genome of
this individual (Figure 5, Text S1). The biology of the INHBB gene
product strongly implicates this mutation as a causal factor but
without additional functional or epidemiological evidence such a
conclusion is speculative (Figure 6).
Setting aside this case of UPD2, we found only modest evidence
for an enrichment of homozygosity in men with spermatogenic
impairment (Figure 4a, Table 3). Our hypothesis was that, if a
large percentage of cases of azoospermia were attributable to
large-effect autosomal recessive Mendelian mutations, we would
see a corresponding increase in the proportion of cases with large
values of F. The average inbreeding coefficient was numerically
higher in each case cohort compared to its matched control cohort
(Table 3). We used a logistic regression mixed model framework to
test for association between autozygosity and disease, while
controlling for population structure, fitting models that treated
autozygosity as both a categorical variable (e.g. inbreeding
coefficient .6.25%, yes or no) and a continuous variable (F,
Methods). While the estimated effect of inbreeding on disease risk
was positive in every model that we tested, the corresponding odds
ratios did not differ significantly from 1 in any version (Table 3).
There were fewer than 10 HBD regions shared by 2 or more cases,
supporting the model that spermatogenic efficiency has a
polygenic basis. We also tested for case-specific aggregation of
HBD segments using the same association framework as that used
for CNVs. We did not identify any significant patterns. Based on
published analyses of small-effect recessive risk mutations in other
complex diseases, we believe our current sample size would be
underpowered to detect association between very old inbreeding
(e.g. due to shared ancestors 15 generations ago). It is possible that
large cohorts, consisting of over 10,000 cases, may be needed to
accurately estimate the relationship between low-level variation in
inbreeding (F values smaller than 0.1) and azoospermia risk, as
well as map specific risk alleles [27,50].
Discussion
We report here the largest whole genome study to date
investigating the role of rare variants in infertility, examining data
from 323 cases of male infertility and 1,136 controls. These data
demonstrate that rare CNVs are a major risk factor for
spermatogenic impairment, and while confirming the central role
of the Y chromosome in modulating spermatogenic output, our risk
estimates for autosomal and X-linked CNVs indicate that this
phenotype is influenced by rare variation across the entire genome.
The controls from two of the cohorts were unphenotyped, and given
the estimated prevalence of azoospermia (1%), we may have
underestimated the risk associated with these large rearrangements.
We observed 5 deletions of DMRT1 coding sequence in cases
and none in over 7,000 controls. These deletions ranged in size
from 54 kb to over 2 Mb (Table 4). DMRT1 is situated in a region
of chromosome 9p that has been identified as a source of
syndromic and non-syndromic forms of XY gonadal dysgenesis
(GD). The deletions of this region that are associated with
syndromic forms of GD are usually 4–10 Mb in size, while isolated
GD has been reported for deletions smaller than 1 Mb [40,51,52].
Despite frequent involvement of DMRT1 in these putative causal
mutations, there is variability in both the phenotypic outcome
Figure 4. Patterns of homozygosity in men with low sperm count. (A) Distribution of the number of HBD regions (HBDRs), and the
proportion of genome contained in these putative HBD regions, plotted for each sample in this study. Replication case and control cohorts are
indicated in the legend. (B) Length distribution of HBDRs detected in all samples combined. Inset, two panels showing probe level intensity data
corresponding to the two largest HBDRs detected. BAF: b-allele frequency, calculated as B/(A+B) where A and B are the approximate copy numbers
for the A and B allele, respectively. The largest HBDR detected corresponds to a case of uniparental disomy of chromosome 2 (UPD2) detected in an
azoospermic man from the Utah cohort.
doi:10.1371/journal.pgen.1003349.g004
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affiliated with each deletion and the extent of DMRT1 coding
sequence contained therein. At least two cases of GD have been
linked to deletions near but not overlapping DMRT1 – one 700 kb
mutation 30 kb distal to DMRT1 in a case of complete XY GD
that was inherited from an apparently normal mother, and a
second 260 kb de novo deletion about 250 kb distal to DMRT1
[39,40]. Both of these deletions overlapped the genes KANK1 and
DOCK8. On the other hand, two smaller deletions, one a 25 kb
deletion of DMRT1 exons 1 and 2, and one a 35 kb deletion of
exons 3 and 4, have been observed in patients with complete GD
and bilateral ovotesticular disorder of sexual development,
respectively [51,52]. Based on the clinical records of patients in
our current study, there is no chance that our DMRT1 deletion
carriers could represent misdiagnosis of a condition as severe as
complete XY GD, which presents with the appearance of female
genitalia. Indeed, two of our DMRT1 deletion carriers were
subject to testicular biopsies. Our observations here suggest that
hemizygous deletion of DMRT1 is a lesion that shows variable
expressivity that may depend on the sequence of the undeleted
DMRT1 allele, variation in other sequences on chromosome 9p,
and the state of other factors in the pathways regulating testicular
development and function. Strictly speaking, statements that
hemizygous deletions of DMRT1 are ‘‘sufficient’’ to cause GD or
spermatogenic failure need to be qualified at this point until we
gain a better understanding of the effects of genetic background.
For instance, in most studies of DMRT1 deletion, the undeleted
DMRT1 allele is rarely sequenced. Is the mode of action dominant
or recessive?
Deletions of the Y chromosome have long been appreciated as a
cause of azoospermia, and we have now shown here that Y-linked
duplications are also significant risk factors for spermatogenic
failure. The precise definition of the duplication sensitive
sequences awaits further investigation. Historically, Y duplications
have been much less studied than Y deletions, as +/2 STS PCR is
the standard assay for assessing Y chromosome copy number
variation in both the clinical and research setting. Quantitative
PCR methods for measuring Y chromosome gene dosage have
been described in the literature, and applied almost exclusively to
studying the phenotypic effects of duplication of genes in the AZFc
region [53]. Results of these investigations are conflicting, with
studies of Europeans reporting no association between AZFc
partial duplication and spermatogenic impairment [54], while
Figure 5. Analysis of exome sequencing data identifies a candidate azoospermia mutation in the case of UPD2.We performed whole-
exome sequencing on the case of UPD2 in an attempt to identify a potential genetic cause for this man’s azoospermia. We constructed a scoring
method to rank order the exome variants in two dimensions: (i) within the set of variants seen in this single exome, the ‘‘Individual Score’’ and (ii)
across a large set of exome sequences, the ‘‘Population Score’’. For each exome variant, the Individual Score, Pind,, was constructed by summing
normalized predictions of functional impact from 5 commonly used annotation algorithms: PhyloP, PolyPhen2, SIFT, GERP, and LRT. This score was
then multiplied by the ploidy of the mutant allele (e.g. 16 for a heterozygous genotype and 26 for a homozygous genotype) creating a final
Individual Score ranging from 0–10. We also calculated the Individual Score for all variation in the 1000 genomes Phase I sequencing data. To
construct the ‘‘Population Score’’ for each variant in the UPD individual, Ppop, we identified the maximum Individual Score variant in the
corresponding gene, Pmax, within the 1000 genomes data, and defined Ppop = Pind2Pmax. The purpose of the Population Score is to scale the
importance of each Individual Score by the extent of pathogenic variation that exists in the population at each gene. Only sites with minor allele
frequencies less than 10% in both the 1000 genomes data and the Exome Variant Server (http://evs.gs.washington.edu/EVS/) were considered in the
analysis. When examining the joint distribution of Ppop and Pind for the UPD2 individual, we saw an enrichment of large scores for variants on
chromosome 2, as expected. The most extreme variant on both scales was a homozygous nonsense mutation in the gene INHBB, the implications of
which we discuss in Figure 6.
doi:10.1371/journal.pgen.1003349.g005
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reproducible associations have been reported in east Asian cohorts
[55,56]. Notably, we identified some duplications on the Y
chromosome greater than 2.5 Mb in size, all spanning the AZFc
locus (Figure S6), in 8/179 cases (those typed on Affymetrix 6.0),
compared to 13/972 controls (OR 3.45 [1.21–9.12], p,0.01).
Rearrangements of this size on the autosomes confer staggering
risk for other forms of disease; for example, by one recent estimate
CNVs larger than 3 Mb have an OR of 47.7 for intellectual
disability and/or developmental delay [46]. Our results suggest
that Y chromosome structure may be more dosage sensitive than
previously appreciated, and we speculate that some genes and
non-coding sequences of the Y chromosome may be under
stabilizing selection for copy number [57].
Three recent studies have used array-based approaches to
characterize CNVs in men with azoospermia. Our finding of an
X-linked CNV burden in men with spermatogenic failure has been
replicated and described elsewhere [58]. In a second study,
Tuttelmann et al. evaluated 89 severe oligozoospermic, 37
azoospermic, and 100 normozoospermic control men using
Agilent 244K and 400K arrays and identified a number of CNVs
potentially involved in male infertility [24]. Third, Stouffs et al.
assayed nine azoospermic men and twenty control samples using
the 244K array and followed-up CNVs of interest by q-PCR in up
to 130 additional controls [25]. Using the criterion of at least 51%
reciprocal overlap, we have identified a number of CNVs in the
current study that overlap with case-specific CNVs in the
Tuttelmann and Stouffs studies. The majority of these CNVs
appear to be relatively common polymorphisms and not case-
specific in our larger dataset; however several noteworthy CNVs
overlap between studies and are absent, or are present at a very
Figure 6. Homozygous missense mutation of INHBB identified in the case of UPD2. (A) We validated this candidate by Sanger sequencing
in the UPD2 case and control individuals. Mutant and reference nucleotides are highlighted within the blue box, confirming the homozygous T to C
nucleotide change observed at chr2:12,1107,305 bp (hg19) of the UPD2 individual. Grey boxes represent the exons of the gene and the red line
indicates the location of the observed mutation within the gene. (B) INHBB encodes for the protein, Inhibin bB, which along with inhibin a and inhibin
bA, combine combinatorially to form the inhibins and activins. Each protein expressed by INHA, INHBA, INHBB consists of an N-terminal signal peptide
(purple), a propeptide (grey), and a subunit chain (green, red or yellow). The mutation identified here results in a M370T change of the inhibin bB
subunit chain (location indicated by a vertical red line throughout the diagram). The various inhibin subunits dimerize via disulfide bonds (locations
indicated by black lines between subunits). As the bB subunit participates in multiple complexes with antagonistic functions, the functional
consequences of loss-of-function or gain-of-function mutations in this protein may be difficult to predict. (C) The role of inhibins and activins in the
hypothalamic-pituitary testicular axis. These complexes have diverse functions in the body, but are most well known for their ability to stimulate and
inhibit follicle stimulating hormone (FSH) production, a process critical for spermatogenesis. Blue arrows connect hormones to the cell or gland by
which they are secreted. Green arrows indicate stimulatory interactions, and red lines indicate inhibitory interactions.
doi:10.1371/journal.pgen.1003349.g006
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low frequency in controls. For example, Tuttelmann et al.
identified a private duplication on Xq22.2 in an oligozoospermic
man [24], and we identified an overlapping duplication in an
oligozoospermic man from the present study (ChrX:103065826–
103205985, NCBI36). These duplications alter the copy number
of a small number of testis-specific or testis-expressed variants of
histone 2B (H2BFWT, H2BFXP, H2BFM). No CNVs in this
region were identified in more than 1600 controls. Tuttelmann et
al. also identified an azoospermic man with a deletion and another
with a duplication on 8q24.3, encompassing the genes PLEC1 and
MIR661 [24]. We identified an oligozoospermic man with a
duplication of the same region, affecting the same functional
elements (chr8:145064091–145118650, NCBI36). CNVs of this
locus are very rare, with a frequency of about 0.005% in our
controls and 0.0025% in controls used for a recent study of
developmental delay [46]. It is important to note that new variants
will frequently be discovered whenever a discovery technology
such as array CGH is applied to a new sample set, and the
observation that a variant is patient-specific is not in itself
remarkable, especially when one is investigating very small sample
sizes.
Our observation of low deletion HI scores in cases raises a
number of considerations for future studies of the genetics of
spermatogenic impairment. We interpret low HI scores in cases as
evidence against a widespread role for dominant, highly penetrant
deletions in spermatogenic failure. It is possible that our case
recruitment, which pre-screened for normal karyotype, may have
removed all large HI score events; however our identification of
two large HI deletions of WT1 and MAPK1 indicate otherwise
(Figure 3). A second concern is that the data used to train the
haploinsufficiency prediction algorithm is in part based on features
of deletions known to cause dominant pediatric disease, and that
an analogous approach trained on fertility phenotypes may lead to
different conclusions. There are few examples of dominant loss-of-
function mutations causing isolated infertility in humans and only
5 of the .200 mouse infertility mutants described in a previous
review showed a phenotype in heterozygous form [45], so fitting a
model of a dominant infertility mutation may be challenging in the
short term. Nonetheless, developing disease-specific pathogenicity
scores for infertility phenotypes should be a priority.
Despite the differences between the genetic signatures of
spermatogenic impairment and severe developmental disease
noted above, there are connections in their epidemiology. Recent
results estimate a 9.9% rate of birth defects in children conceived
by intracytoplasmic sperm injection (ICSI), the technology
typically employed for assisting cases of severe male factor
infertility, which is an OR of 1.77 compared to unassisted
reproduction [59]. Among several possible explanations for this
finding, our data raise the possibility that mutations that
compromise gonadal function may act pleiotropically to disrupt
development in other tissues. A better understanding of the genetic
basis of male infertility is urgently needed in order to improve risk
assessment for couples considering assisted reproduction.
Clinical genomics is a paradigm in need of robust applications,
and our finding of a large CNV burden in cases suggest that some
infertility mutations may have the high penetrance required for
clinical utility. Indeed some mutation screens are already used
clinically in the management of male infertility. Although the
presence of azoospermia can be easily assessed using a standard
laboratory test, many men with azoospermia will have sperm
production within the testis and be candidates for testicular sperm
retrieval. We have already identified that the specific AZF deletion
(a, b or b/c) has a dramatic effect on the prognosis of sperm
Table 3. Summary of inbreeding coefficient estimates across cohorts, and association testing.
F.0.5% F.1.6% F.6.25% All F
Cohort Type Average F # samples # samples # samples # samples
Porto Case 0.0069 39 21 5 175
Spain Control 0.0042 112 41 8 622
Utah Case 0.0020 5 3 1 84
Utah Control 0.0014 0 0 0 59
WUSTL Case 0.0027 6 0 0 70
WUSTL Control 0.0020 1 0 0 99
Effect OR 1.25 (95% CI =
[0.81–1.92])
OR 1.62 (95% CI =
[0.88–2.98])
OR 1.18 (95% CI =
[0.34–4.03])
b= 8.23 (95% CI =
[1.92–14.54])
p value 0.31 0.12 0.794 0.19
For each case and control group we present the average the estimated inbreeding coefficient and the number of individuals with inbreeding coefficients above a
specified threshold. The last column indicates the total number of individuals in each group. The bottom two rows indicate the results of an association test between
inbreeding and case/control status using either a categorical variable as a definition of inbreeding status (F.0.5%, F.1.6%, and F.6.25%) or using the inbreeding
coefficient as a continuous variable (‘‘All F’’).
doi:10.1371/journal.pgen.1003349.t003









U841_A 845091 994958 Illumina 370K 3,4,5 Azoo - SCOS
U162_A 853635 994958 Illumina 370K 3,4,5 Azoo - MA
F1060 861888 916779 Affymetrix 6 3,4 Azoo
F5031 30911 1972069 Affymetrix 6 All Azoo
F3407 30911 1170987 Affymetrix 6 All Azoo
‘DMRT1 Exons’ – exons contained within each deletion, numbered from the 59
to 39 position. SCOS – Sertoli Cell Only Syndrome; MA – maturation arrest.
Deletion coordinates given with respect to NCBI36.
doi:10.1371/journal.pgen.1003349.t004
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retrieval (vs. AZFc-deleted males) [60]. In the present study, we
have identified deletion of DMRT1 coding sequence as a genetic
event that appears highly predictive of spermatogenic failure. In
depth characterization of carriers is now needed to understand
how this mutation affects the prognosis of sperm retrieval. Similar
whole genome tests may provide critical prognostic information
that can help to characterize the chance of successful treatment for
couples with non-obstructive azoospermia, avoiding expensive and
needlessly invasive interventions, while potentially providing
guidance for new therapeutic interventions.
Methods
Ethics statement
All DNA samples used in this study were derived from
peripheral blood lymphocytes collected from individuals giving
IRB-approved informed consent. The following IRBs were
involved: INSA Ethics Committee and Hospital Authority
(Portugal), University of Utah IRB, and Washington University
in St. Louis IRB (#201107177). All samples of genomic DNA to
be analysed in this study i) belong to DNA banks that have been
established throughout the years; ii) are coded; and iii) each
individual has signed a declaration of informed consent before
donating his genomic DNA for analysis, authorizing molecular
studies to be performed with this material.
Patient cohorts
All cases were deemed idiopathic following a standard clinical
workup, which included screening for Y chromosome deletions.
Controls from the Utah cohort were men with normal semen
analysis, remaining controls were not phenotyped on semen
quality. Full details of the source and diagnosis of samples in this
study are available in Supplemental Methods. When using SNP
arrays, CNV analysis is more sensitive to experimental noise than
SNP genotyping, and we used different sample QC metrics to
inform CNV and SNP stages of our project. As a result, we have
slightly larger sample sizes for the HBD analyses than for the CNV
analyses.
Population structure
The individuals studied here were sourced from diverse
geographic locations (Table 1, Text S1). All primary samples
(e.g. 323 cases and 1133 control samples subjected to whole-
genome genetic analysis) were of self-reported Caucasian ancestry,
but it was necessary to take additional steps to control for
population structure in all aspects of the analysis. First, genetic
ancestry of each sample was assessed by principal components
analysis and ethnicity outliers were removed (Figure S2, Figure
S3). Second, eigenvectors generated by this principal components
analysis were used as covariates in both CNV association and
inbreeding coefficient association analyses. For analyses focusing
on the Y chromosome, we performed analyses conditioning on Y
haplogroup to provide the most stringent possible correction for
population structure with available data. Lastly, we conducted
alternate association analyses with the Porto case cohort using a
smaller, but more geographically proximal Spanish control cohort
(Figure S5).
Identification of CNVs, regions of homozygosity-by-
descent
Three array platforms were used for CNV discovery: Illumina
370K (Utah), Illumina OmniExpress (Washington University), and
Affymetrix 6.0 (Porto, Cornell, Nanjing). Full details of sample
processing and array experiments are available in Supplemental
Methods. Three CNV calling algorithms were used to generate
CNV maps for each individual typed with Illumina technology:
GADA, a sparse Bayesian learning approach [61]; PennCNV, a
Hidden Markov Model (HMM)-based method originally designed for
the Illumina platform [62]; and QuantiSNP 2.0, another HMM-
based method for Illumina [63]. CNVs called by 2 of 3 algorithms
were retained for analysis. CNV calling for Affymetrix 6.0 was
performed with Birdsuite [64]. Due to the complexity of calling CNVs
on the sex chromosomes, for all array datasets we implemented a
bespoke normalization and calling procedure that used only the
GADA algorithm to call CNVs from the X and Y chromosomes. For
full details of CNV calling see Supplemental Methods.
Regions of homozygosity-by-descent (HBD) were identified
using BEAGLE 3.0 [48]. SNPs with no-call rates .5% were
removed prior to HBD analysis. As BEAGLE uses a model for
background linkage disequilibrium that is fit from the data, cases
and controls from each cohort were analyzed simultaneously and
separately to assess cohort-specific biases in calling HBD. Prior to
downstream analysis, we identified and removed a small number
of reported HBD regions that corresponded to rare, large
hemizygous deletions.
Inbreeding coefficients for each individual were calculated from
their HBD data using the formula:
F~ total bases in HBDRsð Þ=
2:77|109 total base pairs in SNPmappable genome
 
:
CNV and HBD association analyses
Due to differences in array content, CNV frequencies were
determined on a per-platform basis. All CNV calls made on a
given platform, in both cases and controls, were combined into
CNV regions using a threshold of 50% reciprocal overlap to
defined two events as the same ([35]). We defined the CNV
frequency as the proportion of all samples (cases and controls)
containing that CNV.
We constructed several statistical tests to measure differences
between cases and controls. We used Mann-Whitney U tests to test
for differences in the total amount of aneuploid sequence per
genome. We used standard logistic regression to test for CNV load
on chromosome compartments (e.g. the autosomes, X chromo-
some) and a small number of functional features (genes, miRNA,
etc). To control for population structure these models included the
first 10 principal components from PCA analysis of the SNP
genotype data from all cohorts (Figure S2). We used a permutation
strategy for genomewide, locus-by-locus testing for association at
all genes and in 500 kb non-overlapping genomic windows. The
permutation strategy, implemented with the software package
PLINK, calculates nominal and genomewide p-values by permut-
ing case-control labels [65]. To present consistent summaries of
CNV burden for the entire study (all cohorts combined), we used
linear mixed-effects logistic regression, treating cohort as a random
factor and compared these to effect size estimates for each cohort
separately using standard logistic regression (Figure 1). The mixed
effects modeling framework controls for SNP platform as each
case-control cohort was typed on a different platform; a similar use
of mixed-effect modeling was recently described in a meta-analysis
of schizophrenia SNP data [27].
Analogous tests were conducted on HBD segments from the
original discovery cohort and the combined primary and
replication datasets.
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Validation assay
We performed validation and replication analyses of DMRT1
deletions with and assay based on Taqman PCR. Copy number
was assessed using a pre-designed assay #Hs06833797_cn within
the DMRT1 gene against an RNase P reference (assay # 4403326;
both assays from Applied Biosystems, Carlsbad, CA, USA)
according to manufacturer’s recommendations.
Supporting Information
Dataset S1 Images of the normalized intensity data for all CNV
calls in the Utah case-control cohort .100 kb in size. For each
CNV, we have plotted the Log R Ratio (vertical lines) and B Allele
Frequency (black points) of all probes within the CNV, as well as
an equal number of probes 59 and 39 to the edges of the CNV. The
Log R Ratio for probes within ‘‘gain’’ CNV calls are colored
green, within ‘‘loss’’ CNV calls are colored red, and outside of a
CNV call are colored grey. The sample ID and number of probes
in the CNV call are listed above each image.
(PDF)
Figure S1 QC of Affymetrix callsets. Summary plots of array
QC for the case samples and NBS control samples. There is an
expected inverse correlation between the noise in the data
(measured by the median absolute deviation (MAD) of the probe
intensities) and the number of calls made in a particular
experiment. We fit a linear model to these parameters separately
for cases (A) and NBS controls (C), and samples .4 MADs from
the fitted model were removed (circled dots). We also implemented
an analogous QC step using the ratio of deletions/duplication calls
per sample and number of calls per sample, separately for cases (B)
and NBS controls (D), . In all plots, arrays are colored by their
spatial autocorrelation function (a measure of ‘‘waviness’’).
Distributions of post-QC statistics are highly similar between
cases and controls.
(TIF)
Figure S2 Principal components analysis (PCA) of population
structure in all case cohorts post-QC. For each cohort, samples
were analyzed together with HapMap samples using the
EIGENSOFT package [69]. (A) Utah (B) WUSTL batch 1, (C)
WUSTL batch 2, (D) Porto. Eigenvector loadings for cases and
controls (A,B,C) or cases (D) are plotted as red crosses, while
HapMap samples are plotted as other colored symbols described
in each legend.
(TIF)
Figure S3 Analysis of population structure in the Porto cohort
after sample QC. Based on the results of PCA analysis in Figure
S2D, which indicate that the Portuguese population may have
subtle differences in allele frequencies from northern European
populations, we further investigated the possibility of population
structure as a confounder. No significant correlation was observed
between the estimated amount of African ancestry in each Porto
case and (A) the total number of deletion calls or (B) the total
number of rare deletions (here defined as,5% frequency). In both
cases smaller (more negative) eigenvector loadings (x-axis) indicate
a larger degree of African admixture. We segmented the genome
of each sample into regions with 0, 1 or 2 chromosomes of African
ancestry using the program HapMix [70]. (C) The percent
ancestry inferred by HapMix in this way correlated well with PCA
based ancestry estimates. (D) The extent of African ancestry in
each case, as estimated by EIGENSTRAT, was uncorrelated
(R= 0.002) with the fraction of the genome contained in a
homozygous-by-descent region (a rough measure of the inbreeding
coefficient), indicating that variation in distant African ancestry
was not a major confounder of the HBD analyses.
(TIF)
Figure S4 Analysis of batch effects in Porto cases. The Porto
arrays were run over a period of several months. Here we plot the
total number of CNV calls per array, as a function of run order
(sample number 1= first array run, sample number 162= last
array run). Each dot is colored based on run date. No obvious
outlier batches are visible. There was a small but insignificant
trend for fewer CNV calls on later run dates (least-squares
regression line is plotted).
(TIF)
Figure S5 CNV burden statistics using a Spanish control cohort.
In the primary CNV analyses described in the main text, we use a
Caucasian population from the United Kingdom as a control
group for the Porto azoospermia cohort. Here, we address the
effect of using a control group that is more closely matched on
genetic ancestry. We performed the same burden analyses
depicted in Figure 1 of the main text, this time using a much
smaller control cohort of 368 Caucasian men ascertained in Spain.
We used logistic regression to estimate the influence of copy
number variants (CNVs) on the odds of being diagnosed with
impaired spermatogenesis in three case-control cohorts. Eigenvec-
tors from a principal components analysis were used as covariates
as before. The odds ratio estimated from fitting a logistic
regression model of total CNV count to disease status is plotted
separately for each cohort, as well as the combined set of all
cohorts (black points). Cohort 1 =Utah (Illumina 370K), 2 = Porto
and Weill Cornell (Affymetrix 6.0), 3 =WUSTL (Illumina
OmniExpress). Sample sizes used in CNV analysis are n = 83
cases and n=62 controls for cohort 1, n= 179 cases and 368
controls for cohort 2, and n= 61 cases and 100 controls for cohort
3. Conclusion: While the direction of burden effect for rare
autosomal deletions, X-linked deletions, and Y duplications was
the same as seen with the analysis using UK controls, only the rare
autosomal deletion burden model shows statistical evidence for an
odds ratio greater than 1.
(TIF)
Figure S6 CNVs on the Y chromosome. (A) Our strongest
statistical association involved gains and losses of a 200 kb tandem
repeat termed DYZ19, approximately 500 kb distal to palindrome
P4. Here are plotted 6 deletions from the UT cohort, which were
evenly distributed between azoospermic and oligozoospermic men.
(B) In the Weill-Cornell cohort, a small group of azoospermic
individuals ascertained at a tertiary care clinic, we identified a
number of classical AZF deletions, as well as duplications of AZFc.
Next to each CNV is listed the sample ID and Y haplogroup of the
sample inferred from SNP data (Methods). These data demonstrate
that existing SNP platforms can cleanly identify Y chromosome
rearrangements involving both gain and loss of sequence, and will
facilitate investigation of the full spectrum of Y chromosome
variation in future studies of male infertility. Notably, we observed
complex patterns of copy number change in some samples that
highlight the challenge of interpreting array data mapped to a single
reference Y chromosome (haplogroup R1). In both panels, for each
individual, deviations of probe log2 ratios from 0 are depicted by
grey lines or black dots, and probes spanning CNV calls are colored
as either red (losses) or green (gains).
(TIF)
Figure S7 CNV calls made in all array datasets at the Xp11
rearrangement hotspot. This plot is the same as Figure 2a, with the
addition of tracks containing deletion and duplication calls from a
Genetics of Spermatogenic Impairment
PLOS Genetics | www.plosgenetics.org 13 March 2013 | Volume 9 | Issue 3 | e1003349
Spanish male control cohort assayed on the Affymetrix 6.0
platform.
(TIF)
Figure S8 Left, example STS PCR validation of Xp11 in one
case from Cornell (F10) and two controls. Right, the same assay,
run in multiplex (Xp11 and B-globin reactions in the same tube)
for 5 WUSTL case carriers and two controls. Note the presence of
the smaller beta-globin band in the two control individuals in lanes
7 and 8. The primer sequences for the Xp11 deletion assay and a
control locus are given in the Text S1.
(TIF)
Figure S9 CNV calls made at the DYZ19 tandem repeat locus.
CNV calls made on the Utah, Porto, andWUSTL case cohorts, and
the Utah, NBS (WTCCC), WUSTL and Spanish control cohorts.
(TIF)
Figure S10 qPCR validation of DMRT1 deletions in the Utah
Cohort. (A) Histogram of mean probe intensities from Illumina
370K array spanning the DMRT1/DMRT3 deletion locus
(chr9:845901–994958 bp). N= 148 samples are plotted. (B) Taq-
man validation results for the DMRT1 locus from 30 of the
samples screened by 370K array in panel A (y-axis), including the
two deletion carriers (red points) and one duplication carrier
(green point) identified from Illumina 370K intensity data (x-axis).
(TIF)
Figure S11 CNVs on chromosome 9p in the Nanjing cohort.
Affymetrix 6.0 data was generated on a cohort of 979 idiopathic
NOA cases and ethnicity-matched controls 1734 controls recruited
primarily from the cities of Nanjing and Wuhan, China. CNVs
were called using the identical pipeline as the other cohorts.
Plotted above are all of the deletions (red) and duplications (green)
observed in these cases (top) and controls (bottom).
(TIF)
Figure S12 Detection of additional intronic DMRT1 deletions
using the TaqMan validation assay. As described in the
supplemental methods, we screened 5 plates of DNA from Weill
Cornell cases and 2 plates of Caucasian male controls using the
DMRT1 TaqMan validation assay. Each sample was assayed in
quadruplicate (although some samples were assayed in duplicate
or triplicate if insufficient DNA was available). We applied
extremely stringent calling criteria to these data, excluding
samples with (1) low DNA content as defined by picogreen assay
(2) high standard deviation (.0.3) of delta CT measurements
across replicates (3) low copy number confidence scores generated
by CopyCaller software. Each point in the panels above
represents the average delta CT for the control locus (VIC) and
DMRT1 (FAM) for a single sample. Red dots indicate deletion
carrier calls. We detected 2 deletions in 233 case samples, a
frequency of 0.86%, and 1 deletion in 135 controls (0.74%). As
this assay is targeting intronic sequence, and we have not cloned
the breakpoints the functional consequences of each deletion is
unclear.
(TIF)
Figure S13 Controlling for population structure while testing for
association between inbreeding and infertility. As described in Figure
S2 and in Text S1, we used principal components analysis to assess
population structure in our case and control cohorts. We use the
BEAGLE software package to define homozygous-by-descent regions
(HBDRs) of each sample in our study, and used these HBDRs to
estimate corresponding inbreeding coefficients. We tested for
association between inbreeding coefficient and the probability of
azoospermia using a linear model. On the left, we show that there is
strong association when analyzing data from the Porto cases and NBS
WellcomeTrust case-control consortium controls (CCC controls) in a
simple model that does not account for population structure (‘‘No
EV’’). When including the first 10 eigenvectors from a PCA analysis
(‘‘EV’’), the point estimate of association remains somewhat inflated
but is no longer significant. On the right, we show the same analysis
performed on the Porto cohort with a more closely matched control
population from Spain, with clearly smaller confidence intervals and
smaller point estimates of effect size. In order to be as conservative as
possible, we report results of inbreeding analysis using the Spanish
control cohort in the main text.
(TIF)
Table S1 The results of CNV burden tests performed on the
Utah cohort. Each subtable contains summary statistics for a
different subset of CNVs, selected by size and/or frequency.
(XLSX)
Table S2 The results of CNV burden tests performed on the
Porto cohort. Each subtable contains summary statistics for a
different subset of CNVs, selected by size and/or frequency.
(XLSX)
Table S3 The results of CNV burden tests performed on the
Washington University cohort. Each subtable contains summary
statistics for a different subset of CNVs, selected by size and/or
frequency.
(XLSX)
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